01.10.2020
We are pleased to announce that Prof. Dr. Jan Torzewski of the Klinikum Kempten and Klinik Immenstadt from the Klinikverbund Allgäu has been nominated for the German Medical Award.
12.09.2020
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).
30.08.2020
In the scientific journal Frontiers in Immunology an article was published in which the effect of human CRP on blood pressure and heart rate of rabbits was investigated.
25.08.2020
On August 25, 2010, Dr. Ahmed Sheriff together with Birgit Vogt, Dr. Rudolf Kunze, Stephan Hiller and Dr. Bernd Wegener founded Pentracor GmbH to implement the idea of CRP apheresis for acute inflammation-driven diseases such as myocardial infarction.
07.06.2020
In the American Journal of Case Reports the application of PentraSorb® CRP in a COVID-19 patient published.
25.05.2020 - In an interview with the corporate bond portal BondGuide, company founder and CEO Ahmed Sheriff talks about the reasons for the bond issue and the company's business plan:
New issue of Pentracor: "We are the first and so far the only ones who have succeeded".
22.05.2020 - In an interview with the bond platform Bond Finder, company founder Ahmed Sheriff talks about the background to the bond issue and explains why going to the capital market is the next logical step in the company's development:
„Our medical device innovation is unrivalled" - Interview with Dr. Ahmed Sheriff, Pentracor GmbH
22 May 2020 - In an interview with the stock market portal 4investors, Pentracor CEO Ahmed Sheriff and CFO Sven Haevernick explain their plans for the new bond, the future corporate goals and the global market potential of PentraSorb® CRP:
"Pentracor: IPO would be a logical step - FMC among investors"
15.04.2020
In the programme of 15 April 2020, CRP apheresis was presented as an option for the treatment of COVID-19. Furthermore, Professor Garlichs, Chief Physician of the Medical Clinic - Internal Medicine of the Diakonissenkrankenhaus in Flensburg, presented the results of the CAMI 1 study. The approx.
